09/12/10 - CellCentric Featured in Nature Biotechnology
A new review of second generation epigenetic targets highlights CellCentric as a key leader in a field which is becoming a strategic research and development imperative for many pharmaceutical companies.
- Read more
01/12/10 - Cellnovo's mobile health approach to diabetes care
Cellnovo is aiming to be the iTunes of diabetes care, aiming to transform the piecemeal management of the disease.
- Read more
18/11/10 - CellCentric Publishes on Non-Oncology Indications
CellCentric's Scientific Director Nessa Carey and Programme Manager Jonathan Best publish a review on epigenetics and non-oncology therapeutic indications in Drug Discovery Today.
- Read more
05/11/10 - Wellcome Trust and investors back development of new surgical haemostat
Haemostatix Ltd, a biopharmaceutical company, announced today that it has received a £409,000 Translation Award from the Wellcome Trust to support development of its innovative haemostat technology.
- Read more
15/10/10 - Dexela Wins British Engineering Excellence Award
Dexela collected the Judges’ Special Award at the British Engineering Excellence Awards (BEEA) and received a special commendation in the Small Company of the Year category. The awards aim to demonstrate and promote the quality of engineering design within the UK
- Read more
11/10/10 - Light Blue Optics raises US$13 million to realise growing list of new applications for Light Touch™
Light Blue Optics (LBO) today announced it has raised US$13 million in funding. The money will enable LBO to continue building out market opportunities for its Gen 1 products – Light Touch™ and Light Work™ – and accelerate its Gen 2 product development roadmap for embedded interactive projection devices. This funding follows the Company’s previous Series ‘A’ extension of $15 million in July 2009.
-Read more
03/10/10 - Sirigen Announces the completion of Financing Worth £3.83 Million and New Directors
Hampshire based medical technology company Sirigen Group Ltd has completed two financing rounds totalling £3.83 million. These rounds were led by a syndicate of new investors comprising IQ Capital, NESTA (National Endowment for Science, Technology and the Arts) and YFM Private Equity alongside existing investors, Seraphim Capital and Oxford Capital Partners.
- Read more
20/09/2010 - Aquapharm and Dundee University Sign Research Collaboration to find Marine Compounds to target Alzheimer's
Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it has signed a research agreement with Dundee University to help it develop new drugs based on marine natural products that may help in the fight against Alzheimer's.
-Read more
17/09/10 - Dexela shortlisted for British Engineering Excellence Awards
Dexela has been shortlisted for three categories in the British Engineering Excellence Awards, which have been created to celebrate the great achievements of the UK's design engineers.
- Read more
31/08/10 - CellCentric’s Scientific Founder Awarded Royal Medal
Prof Azim Surani FRS CBE has been awarded the Royal Society’s Royal Medal for his pivotal contributions to the understanding of early mammalian development.
- Read more
13/08/10 - Plaxica announces closing of £3 million Series A financing
Plaxica announced that it raised a further £3 million in a Series A financing in which all existing institutional investors participated. The funds will be used to accelerate development and scale up of the company’s next generation PLA technology. John Hamlin, CEO of Plaxica said "having made solid technical and commercial progress over the recent months, I am delighted that our investors have provided significant further funding to allow the rapid development and scale up of Plaxica’s technology. The industrial interest we continue to experience demonstrates the significant level of demand for the company’s PLA technology".
- Read more Plaxica news
09/07/10 - NESTA's Venture Capital report launched examining the current tough VC climate, and the opportunites for growth in hi-tech
There is positive news to emerge from our research. Funds made good returns on exits in the middle of the recession so with a peak of investment activity between 2004 and 2007 many funds will be able to harvest their portfolio. Hopefully, this will coincide with economic growth and renewed M&A activity.
-Read more
08/07/2010 - Venture capital activity worse than dotcom era
UK start ups saw a 40 per cent decline in venture capital activity in the past two years according to new research by NESTA.
-Read more
07/07/10 - Aquapharm signs research agreement with AMRI
Aquapharm Biodiscovery, a leading marine biotechnology company, announces that it has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm's marine natural products library.
-Read the full article
July 2010 - Light Blue Optics was named 16th most creative company in CNBC's list of Europe's 25 Most Creative Companies.
The full article can be viewed on the CNBC website.
24/06/10 - eoSemi wins £3m investment round to bring new silicon-based timing device to market
Yorkshire-based semiconductor company eoSemi has closed a £3m funding round led by NESTA Investments and Capital-E alongside existing investors Enterprise Ventures ("EV") via its RisingStars Growth Fund II and South Yorkshire Investment Fund.
-Read more
08/10/2009 - Plaxica secures £1m funding to develop next generation renewable polymers
Plaxica has raised £1m in equity funding from existing investor Imperial Innovations Group plc, and new investors, Carbon Trust Investments Limited and NESTA.
-Read more
T +44 (0)20 7438 2500
F +44 (0)20 7438 2501
Nesta Operating Company, a company limited by guarantee registered in England and Wales with company number 7706036 and charity number 1144091. Registered as a charity in Scotland number SC042833.
